(CEMRV) A 3D dynamic contrast enhanced magnetic resonance venogram with acquisition timing to account for the later arrival of the contrast agent in the venous system. The pulse sequence used, is an enhanced 3D fast gradient echo sequence, the same sequence that is used for MR angiography.

For Ultrasound Imaging (USI) see Venous Ultrasound at Medical-Ultrasound-Imaging.com.

Contrast enhanced MRI is a commonly used procedure in magnetic resonance imaging. The need to more accurately characterize different types of lesions and to detect all malignant lesions is the main reason for the use of intravenous contrast agents.
Some methods are available to improve the contrast of different tissues. The focus of dynamic contrast enhanced MRI (DCE-MRI) is on contrast kinetics with demands for spatial resolution dependent on the application. DCE-MR imaging is used for diagnosis of cancer (see also liver imaging, abdominal imaging, breast MRI, dynamic scanning) as well as for diagnosis of cardiac infarction (see perfusion imaging, cardiac MRI). Quantitative DCE-MRI requires special data acquisition techniques and analysis software.
Contrast enhanced magnetic resonance angiography (CE-MRA) allows the visualization of vessels and the temporal resolution provides a separation of arteries and veins. These methods share the need for acquisition methods with high temporal and spatial resolution.
Double contrast administration (combined contrast enhanced (CCE) MRI) uses two contrast agents with complementary mechanisms e.g., superparamagnetic iron oxide to darken the background liver and gadolinium to brighten the vessels. A variety of different categories of contrast agents are currently available for clinical use.
Reasons for the use of contrast agents in MRI scans are:
Common Indications:
Brain MRI : Preoperative/pretreatment evaluation and postoperative evaluation of brain tumor therapy, CNS infections, noninfectious inflammatory disease and meningeal disease.
Spine MRI : Infection/inflammatory disease, primary tumors, drop metastases, initial evaluation of syrinx, postoperative evaluation of the lumbar spine: disk vs. scar.
Breast MRI : Detection of breast cancer in case of dense breasts, implants, malignant lymph nodes, or scarring after treatment for breast cancer, diagnosis of a suspicious breast lesion in order to avoid biopsy.

For Ultrasound Imaging (USI) see Contrast Enhanced Ultrasound at Medical-Ultrasound-Imaging.com. See also Blood Pool Agents, Myocardial Late Enhancement, Cardiovascular Imaging, Contrast Enhanced MR Venography, Contrast Resolution, Dynamic Scanning, Lung Imaging, Hepatobiliary Contrast Agents, Contrast Medium and MRI Guided Biopsy.

Magnetic resonance imaging (MRI) is based on the magnetic resonance phenomenon, and is used for medical diagnostic imaging since ca. 1977 (see also MRI History).
The first developed MRI devices were constructed as long narrow tunnels. In the meantime the magnets became shorter and wider. In addition to this short bore magnet design, open MRI machines were created. MRI machines with open design have commonly either horizontal or vertical opposite installed magnets and obtain more space and air around the patient during the MRI test.
The basic hardware components of all MRI systems are the magnet, producing a stable and very intense magnetic field, the gradient coils, creating a variable field and radio frequency (RF) coils which are used to transmit energy and to encode spatial positioning. A computer controls the MRI scanning operation and processes the information.
The range of used field strengths for medical imaging is from 0.15 to 3 T. The open MRI magnets have usually field strength in the range 0.2 Tesla to 0.35 Tesla. The higher field MRI devices are commonly solenoid with short bore superconducting magnets, which provide homogeneous fields of high stability.
There are this different types of magnets:
The majority of superconductive magnets are based on niobium-titanium (NbTi) alloys, which are very reliable and require extremely uniform fields and extreme stability over time, but require a liquid helium cryogenic system to keep the conductors at approximately 4.2 Kelvin (-268.8° Celsius). To maintain this temperature the magnet is enclosed and cooled by a cryogen containing liquid helium (sometimes also nitrogen).
The gradient coils are required to produce a linear variation in field along one direction, and to have high efficiency, low inductance and low resistance, in order to minimize the current requirements and heat deposition. A Maxwell coil usually produces linear variation in field along the z-axis; in the other two axes it is best done using a saddle coil, such as the Golay coil.
The radio frequency coils used to excite the nuclei fall into two main categories; surface coils and volume coils. The essential element for spatial encoding, the gradient coil sub-system of the MRI scanner is responsible for the encoding of specialized contrast such as flow information, diffusion information, and modulation of magnetization for spatial tagging.
An analog to digital converter turns the nuclear magnetic resonance signal to a digital signal. The digital signal is then sent to an image processor for Fourier transformation and the image of the MRI scan is displayed on a monitor.

For Ultrasound Imaging (USI) see Ultrasound Machine at Medical-Ultrasound-Imaging.com.

See also the related poll results: 'In 2010 your scanner will probably work with a field strength of' and 'Most outages of your scanning system are caused by failure of'

From ISOL Technology
'Ultra high field MR system, it's right close to you. FORTE 3.0T is the new standard for the future ultra high field MR system. If you are pushing the limits of your existing clinical MR scanner, the FORTE will surely take you to the next level of diagnostic imaging. FORTE is the core leader of the medical technology in the 21st century. Proving effects of fMRI that cannot be measured with MRI less than 2.0T.'

Short name: Ami 227, generic name: Ferumoxtran, (USPIO)
Ferumoxtran is a substance of the class of ultrasmall superparamagnetic iron oxide used as a lymph node specific contrast agent for MRI.
See also Combidex®, Sinerem® and Ultrasmall Superparamagnetic Iron Oxide.
Partner(s): Cytogen Corporation, National Cancer Institute. An approvable letter was received from the U.S. Food and Drug Administration for Combidex in June 2000. Advanced Magnetics, Inc. has submitted a complete response to the approvable letter received from the U.S. Food and Drug Administration, which was accepted by the FDA and assigned a user fee goal date of March 30, 2005. In Europe, a Dossier (the European equivalent of a NDA) was submitted by Advanced Magnetics' European partner, Guerbet SA, to the European Medicines Evaluations Agency in December 1999. (Sinerem® is the brand name for this USPIO in Europe manufactured by Guerbet, Combidex® by Advanced Magnetics for the U.S. market)
Advanced Magnetics, Inc. changed its name in July 2007 to AMAG Pharmaceuticals Inc.